Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Living cheaply while in debt is possible with the right strategies. Discover how to manage your finances effectively during tough times.
28,482 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
A Harvard professor decodes the squeak that haunts basketball courts, tying micro-deformations in the sole to the son...
Kick off your weekend with focused, actionable investing reads. This guide helps you pick credible sources, turn insi...
When dollar general stock dips, investors often worry about consumer weakness or policy shifts. This guide breaks dow...
History says you'll regret not buying Amazon stock if you wait for perfect timing. This guide breaks down the lessons...
BioCryst faces a pivotal year. This practical guide breaks down what biocryst (bcrx) 2026 earnings could mean for inv...
XRP on-chain activity climbs to a fresh milestone as big holders stock up, even as the price slips under $1.45. The m...
Figma’s latest revenue surge has caught the eye of investors staring at a beaten-down stock. This article breaks down...
Mortgage rates rose again this week as inflation fears and geopolitical tensions weighed on bonds. The latest Freddie...
Former President Donald Trump publicly supports CFTC Chair Michael Selig's push to widen federal control over predict...
As markets wobble in mid-2026, retirees rethink growth bets tied to gig-economy platforms. The retirement portfolio c...
The CLARITY Act fight over crypto ethics stalled as lawmakers clashed on enforcement and state powers, leaving invest...